Deep sequencing of immune receptor rearrangements in lymphocyte populations provides a direct and sensitive tool to characterize and define antibody responses to HIV-1. Despite being found in -20% of chronically infected subjects, it has not yet been possible to induce broadly neutralizing antibodies (BnAbs) by vaccination. Moreover, there is increasing evidence that their expression may be controlled by a variety of immunoregulatory mechanisms and/or their maturation pathways are limited by the number of somatic hypermutations that must accrue. The B Cell Focus Team will isolate the native heavy and light chain antibodies using recombinant antibody technology, and this Antibody Sequencing Scientific Research Support Component will perform 454 deep sequencing to elucidate the full extent of depth and breadth of potentially protective HIV-1 antibody clonal lineages.
Specific Aims Aim 1,To define maturation pathways of BnAb HIV-1 antibodies by performing 454 deep sequencing of immunoglobulin (Ig) variable (V) heavy (H) rearrangements using B cells from HIV-1-infected individuals who are capable of making BnAbs.
Aim 2. To perform 454 deep sequencing of Ig VH rearrangements of B cell repertoires in Env- vaccinated individuals to define maturation pathways of potentially protective HIV-1 antibodies.
Aim 3. To perform 454 deep sequencing of immunoglobulin (Ig) variable (V) heavy (H) rearrangements in HI V-1-infected subjects who do and do not develop BnAbs, and to correlate this information with HIV-1 Env quasispecies complexity in these same individuals;this will allow us to determine to what extent neutralization escape mutations drive BnAb induction.

Public Health Relevance

Development of an HIV-1 vaccine able to induce antibodies active against a broad range of viral variants would be a major breakthrough in combating this disease. The Antibody Sequencing Support Component will use new DNA sequencing methods to thoroughly characterize broadly-neutralizing HlV-1 antibodies that arise in some infected patients, to determine their origin and pathways of development. Paired with sequencing of viruses present in such patients, and structural studies, our data should enable better-informed design of vaccines to stimulate B cells toward generation of broadly-neutralizing antibodies.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Chen, Jia; Frey, Gary; Peng, Hanqin et al. (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 88:1249-58
Hraber, Peter; Seaman, Michael S; Bailer, Robert T et al. (2014) Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-9
Pollara, Justin; Bonsignori, Mattia; Moody, M Anthony et al. (2014) HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88:7715-26
Verkoczy, Laurent; Diaz, Marilyn (2014) Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS 9:224-34
Hwang, Kwan-Ki; Trama, Ashley M; Kozink, Daniel M et al. (2014) IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. PLoS One 9:e90725
Haynes, Barton F; Moody, M Anthony; Alam, Munir et al. (2014) Progress in HIV-1 vaccine development. J Allergy Clin Immunol 134:3-10; quiz 11
Holl, T Matt; Yang, Guang; Kuraoka, Masayuki et al. (2014) Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-79
Roederer, Mario; Keele, Brandon F; Schmidt, Stephen D et al. (2014) Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-8
Dennison, S Moses; Anasti, Kara M; Jaeger, Frederick H et al. (2014) Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. J Virol 88:9406-17
Fera, Daniela; Schmidt, Aaron G; Haynes, Barton F et al. (2014) Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci U S A 111:10275-80

Showing the most recent 10 out of 48 publications